Jones R N, Hoban D J
Medical Microbiology Division, University of Iowa College of Medicine, Iowa City.
Diagn Microbiol Infect Dis. 1994 Jan;18(1):49-56. doi: 10.1016/0732-8893(94)90133-3.
Ofloxacin, a newer broad-spectrum fluoroquinolone, was evaluated against > 12,000 clinical isolates in a multicenter surveillance trial in the United States and Canada using the standardized disk diffusion method. A total of 53 geographically diverse clinical microbiology laboratories contributed zone diameter results for ofloxacin, ciprofloxacin, and norfloxacin for urinary tract infection (UTI) isolates; and ofloxacin and ciprofloxacin for respiratory tract infection (RTI) isolates, skin and soft tissue infection (SSTI) isolates, and genital tract pathogen isolates. In both the USA and Canada, ofloxacin was shown to have the wide spectrum of activity as follows: RTI isolates, ofloxacin (92.2%-93.8% susceptible) > ciprofloxacin (89.5%-90.4%); SSTI isolates, ofloxacin (87.1%-93.6%) > ciprofloxacin (78.8%-90.4%); UTI isolates, ofloxacin (91.6%-92.5%) > norfloxacin (87.3%-91.7%) > ciprofloxacin (86.4%-89.7%); and genital tract isolates, ofloxacin (94.0%) > ciprofloxacin (85.4%) (Canada only). US strains resistant to ofloxacin were confirmed by reference laboratory tests. Confirmed ofloxacin resistance, other than among staphylococci or nonenteric bacilli, was rare. The species most often found to be resistant to both ofloxacin and ciprofloxacin were methicillin-resistant staphylococci, Acinetobacter spp., and Enterococcus spp. From these contributing US and Canadian laboratory studies, ofloxacin appears to have a balanced spectrum of potential clinical use (91.8% susceptible aerobic isolates), particularly against Gram-positive pathogens and some species resistant to ciprofloxacin. The combined overall isolate (12,241 isolates) rates of susceptibility for ciprofloxacin (four infection sites) and norfloxacin (UTI only) were 87.3% and 88.8%, respectively. Monitoring for increasing fluoroquinolone resistance should be considered, however, as greater use of drugs in this class develops.
氧氟沙星是一种新型广谱氟喹诺酮类药物,在美国和加拿大进行的一项多中心监测试验中,采用标准化纸片扩散法对12000多株临床分离菌株进行了评估。共有53个地理位置分散的临床微生物实验室提供了氧氟沙星、环丙沙星和诺氟沙星对尿路感染(UTI)分离菌株的抑菌圈直径结果;以及氧氟沙星和环丙沙星对呼吸道感染(RTI)分离菌株、皮肤和软组织感染(SSTI)分离菌株和生殖道病原体分离菌株的抑菌圈直径结果。在美国和加拿大,氧氟沙星均显示出广泛的活性谱如下:对于RTI分离菌株,氧氟沙星(92.2%-93.8%敏感)>环丙沙星(89.5%-90.4%);对于SSTI分离菌株,氧氟沙星(87.1%-93.6%)>环丙沙星(78.8%-90.4%);对于UTI分离菌株,氧氟沙星(91.6%-92.5%)>诺氟沙星(87.3%-91.7%)>环丙沙星(86.4%-89.7%);对于生殖道分离菌株,氧氟沙星(94.0%)>环丙沙星(85.4%)(仅在加拿大)。对氧氟沙星耐药的美国菌株通过参考实验室检测得到确认。除葡萄球菌或非肠道杆菌外,确认的氧氟沙星耐药情况很少见。最常发现对氧氟沙星和环丙沙星均耐药的菌种是耐甲氧西林葡萄球菌、不动杆菌属和肠球菌属。从美国和加拿大这些参与研究的实验室研究来看,氧氟沙星似乎具有平衡的潜在临床应用谱(91.8%的需氧分离菌株敏感),尤其对革兰氏阳性病原体和一些对环丙沙星耐药的菌种有效。环丙沙星(四个感染部位)和诺氟沙星(仅UTI)的合并总体分离菌株(12241株分离菌株)敏感性率分别为87.3%和88.8%。然而,随着这类药物使用的增加,应考虑监测氟喹诺酮耐药性的增加情况。